Azilect helps "double 2nd-line MAO-Bs in PD"

Decision Resources says that second-line Parkinson's disease patient's share of monoamine oxidase-B inhibitors has increased from 14.1% to  35.2% since last year.

According to a survey conducted by the US drug industry advisory firm,  most of this increased patient share was driven by growth in the use of  Teva's Azilect (rasagiline) thanks to physicians' growing comfort with  the drug and data attesting to possible disease-modifying effects.

"Neurologists are likely the driving force behind this increase in  Azilect prescription, as only 8% of surveyed primary care physicians  report using the drug," said Madhuri Borde, analyst at Decision  Resources. "In fact, Azilect prescriptions will likely continue to rise  in the specialist setting as 55% of surveyed neurologists believe that  the ADAGIO trial results demonstrated Azilect has a disease-modifying  effect and will increase their Azilect prescriptions as a result," he  added.